Clinical Trial Update: Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis [Phase 2]

View source ↗

Summary

Phase 2b trial evaluating ISB 830 for adults with moderate to severe atopic dermatitis has completed with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• ISB 830

Snippet

Sponsor: Ichnos Sciences SA | Conditions: Moderate to Severe Atopic Dermatitis | Phase 2 | Status: COMPLETED | Results posted: 2022-06-28